Certara Enters Strategic Partnership with Biowaived to Increase Biopharmaceutics Capabilities

Radnor, PA – [2025 年 3 月 17 日] – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in model-informed drug development, has announced a strategic partnership with Biowaived, a biopharmaceutics and dissolution strategies contract research organization. Through this partnership, Certara and Biowaived clients will gain access to collaborative services that support biopharmaceutics, formulation, and bioequivalence assessments in drug development. This partnership combines Certara’s industry-leading biopharmaceutical simulation tools and services with Biowaived’s state-of-the-art lab-based experimental capabilities. offering a seamless integrated solution to streamline the drug development process.

Certara’s products and services span the drug development workflow. Certara’s solutions are increasingly adopted in biopharmaceutics, providing comprehensive support across various stages. These include early formulation development, forecasting food and formulation effects, establishing virtual bioequivalence, and facilitating bridging and biowaiver strategies. Biowaived provides biopharmaceutics and dissolution laboratory-based data to support product development. This strategic partnership accelerates Certara’s innovation in biopharmaceutics by seamlessly integrating assay development and data production in line with biosimulation solutions.